STANDARD BIOTOOLS INC (LAB)
US34385P1084 - Common Stock
Taking everything into account, LAB scores 2 out of 10 in our fundamental rating. LAB was compared to 58 industry peers in the Life Sciences Tools & Services industry. LAB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LAB is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year LAB has reported negative net income.
LAB had a negative operating cash flow in the past year.
In the past 5 years LAB always reported negative net income.
In the past 5 years LAB always reported negative operating cash flow.
1.2 Ratios
LAB's Return On Assets of -23.23% is on the low side compared to the rest of the industry. LAB is outperformed by 63.79% of its industry peers.
LAB's Return On Equity of -32.27% is on the low side compared to the rest of the industry. LAB is outperformed by 60.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.23% | ||
| ROE | -32.27% | ||
| ROIC | N/A |
ROA(3y)-31.11%
ROA(5y)-26.82%
ROE(3y)-63.68%
ROE(5y)-54.27%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LAB has a Gross Margin (46.66%) which is in line with its industry peers.
LAB's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for LAB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.66% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.69%
GM growth 5Y-2.74%
2. Health
2.1 Basic Checks
LAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LAB has been increased compared to 1 year ago.
Compared to 5 years ago, LAB has more shares outstanding
LAB has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.29, we must say that LAB is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.29, LAB is not doing good in the industry: 68.97% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.00 indicates that LAB is not too dependend on debt financing.
The Debt to Equity ratio of LAB (0.00) is better than 79.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.29 |
ROIC/WACCN/A
WACC10.02%
2.3 Liquidity
LAB has a Current Ratio of 3.88. This indicates that LAB is financially healthy and has no problem in meeting its short term obligations.
LAB has a Current ratio of 3.88. This is in the better half of the industry: LAB outperforms 63.79% of its industry peers.
LAB has a Quick Ratio of 3.53. This indicates that LAB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.53, LAB is in the better half of the industry, outperforming 65.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.88 | ||
| Quick Ratio | 3.53 |
3. Growth
3.1 Past
LAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.67%.
The Revenue has grown by 29.25% in the past year. This is a very strong growth!
The Revenue has been decreasing by -1.21% on average over the past years.
EPS 1Y (TTM)-16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
Revenue 1Y (TTM)29.25%
Revenue growth 3Y-8.34%
Revenue growth 5Y-1.21%
Sales Q2Q%35.36%
3.2 Future
The Earnings Per Share is expected to grow by 18.57% on average over the next years. This is quite good.
Based on estimates for the next years, LAB will show a very strong growth in Revenue. The Revenue will grow by 31.85% on average per year.
EPS Next Y45.34%
EPS Next 2Y32.01%
EPS Next 3Y23.95%
EPS Next 5Y18.57%
Revenue Next Year66.49%
Revenue Next 2Y38.78%
Revenue Next 3Y31.51%
Revenue Next 5Y31.85%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
LAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LAB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
LAB's earnings are expected to grow with 23.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.01%
EPS Next 3Y23.95%
5. Dividend
5.1 Amount
LAB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
STANDARD BIOTOOLS INC
NASDAQ:LAB (9/18/2024, 8:12:14 PM)
After market: 2.03 0 (0%)2.03
+0.03 (+1.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap753.43M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.23% | ||
| ROE | -32.27% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.66% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.88 | ||
| Quick Ratio | 3.53 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-16.67%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y45.34%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)29.25%
Revenue growth 3Y-8.34%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y